BioStock: DexTech Medical’s CEO on the company’s platform technology

DexTech Medical develops drug candidates in oncology that are based on the CDC platform GuaDex, where different substances are combined with the carbohydrate molecule dextran. The company will soon advance into the clinical phase in multiple myeloma with the main candidate OsteoDex, which has shown promising phase II clinical results in metastatic castration-resistant prostate cancer. BioStock contacted DexTech’s CEO Anders R Holmberg to find out more.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/02/dextech-medicals-ceo-on-the-companys-platform-technology/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se